These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9585393)

  • 41. Effectiveness and safety of human umbilical cord-mesenchymal stem cells for treating type 2 diabetes mellitus.
    Lian XF; Lu DH; Liu HL; Liu YJ; Han XQ; Yang Y; Lin Y; Zeng QX; Huang ZJ; Xie F; Huang CH; Wu HM; Long AM; Deng LP; Zhang F
    World J Diabetes; 2022 Oct; 13(10):877-887. PubMed ID: 36312002
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human islet amyloid polypeptide: A therapeutic target for the management of type 2 diabetes mellitus.
    Roham PH; Save SN; Sharma S
    J Pharm Anal; 2022 Aug; 12(4):556-569. PubMed ID: 36105173
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Establishment and validation of a nomogram that predicts the risk of type 2 diabetes in obese patients with non-alcoholic fatty liver disease: a longitudinal observational study.
    Cai X; Wang M; Liu S; Yuan Y; Hu J; Zhu Q; Hong J; Tuerxun G; Ma H; Li N
    Am J Transl Res; 2022; 14(7):4505-4514. PubMed ID: 35958467
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Insulin resistance and beta-cell dysfunction in newly diagnosed type 2 diabetes: Expression, aggregation and predominance. Verona Newly Diagnosed Type 2 Diabetes Study 10.
    Bonora E; Trombetta M; Dauriz M; Brangani C; Cacciatori V; Negri C; Pichiri I; Stoico V; Rinaldi E; Da Prato G; Boselli ML; Santi L; Moschetta F; Zardini M; Bonadonna RC
    Diabetes Metab Res Rev; 2022 Oct; 38(7):e3558. PubMed ID: 35717608
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improvement of beta-cell function in conjunction with glycemic control after medical nutrition therapy in newly-diagnosed type 2 diabetes mellitus.
    Takahara M; Shiraiwa T; Maeno Y; Yamamoto K; Shiraiwa Y; Yoshida Y; Nishioka N; Katakami N; Shimomura I
    BMC Endocr Disord; 2022 Jun; 22(1):150. PubMed ID: 35658859
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Class I MHC Polymorphisms Associated with Type 2 Diabetes in the Mexican Population.
    Mendoza-Ramírez P; López-Olaiz MA; Morales-Fernández AL; Flores-Echiveste MI; de Jesus Casillas-Navarro A; Pérez-Rodríguez MA; de Jesús Orozco-Luna F; Cortés-Romero C; Zuñiga LY; Sanchez Parada MG; Hernandez-Ortega LD; Mercado-Sesma AR; Baptista-Rosas RC
    Genes (Basel); 2022 Apr; 13(5):. PubMed ID: 35627158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Associations of the HOMA2-%B and HOMA2-IR with progression to diabetes and glycaemic deterioration in young and middle-aged Chinese.
    Fan B; Wu H; Shi M; Yang A; Lau ESH; Tam CHT; Mao D; Lim CKP; Kong APS; Ma RCW; Chow E; Luk AOY; Chan JCN
    Diabetes Metab Res Rev; 2022 Jul; 38(5):e3525. PubMed ID: 35174618
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patient characteristics associated with improvement in glycemic control following addition of an oral antidiabetic drug to DPP-4 inhibitor monotherapy in Japanese patients with type 2 diabetes mellitus (JDDM 60).
    Kawai K; Eiki JI; Kanatsuka A; Motohashi S; Wakana A; Hayashi A; Iglay K; Yamazaki K; Tokita S; Maegawa H;
    Diabetol Int; 2022 Jan; 13(1):132-141. PubMed ID: 35059249
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glucose Regulates m
    Bornaque F; Delannoy CP; Courty E; Rabhi N; Carney C; Rolland L; Moreno M; Gromada X; Bourouh C; Petit P; Durand E; Pattou F; Kerr-Conte J; Froguel P; Bonnefond A; Oger F; Annicotte JS
    Cells; 2022 Jan; 11(2):. PubMed ID: 35053407
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants.
    Felton JL; Cuthbertson D; Warnock M; Lohano K; Meah F; Wentworth JM; Sosenko J; Evans-Molina C;
    Diabetologia; 2022 Jan; 65(1):88-100. PubMed ID: 34642772
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glycemic control and its association with sociodemographics, comorbid conditions, and medication adherence among patients with type 2 diabetes in southwestern Nigeria.
    Ibrahim AO; Agboola SM; Elegbede OT; Ismail WO; Agbesanwa TA; Omolayo TA
    J Int Med Res; 2021 Oct; 49(10):3000605211044040. PubMed ID: 34632841
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Telmisartan Potentiates Insulin Secretion via Ion Channels, Independent of the AT1 Receptor and PPARγ.
    Liu T; Cui L; Xue H; Yang X; Liu M; Zhi L; Yang H; Liu Z; Zhang M; Guo Q; He P; Liu Y; Zhang Y
    Front Pharmacol; 2021; 12():739637. PubMed ID: 34594226
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: A population-based observational study.
    Ke C; Stukel TA; Shah BR; Lau E; Ma RC; So WY; Kong AP; Chow E; Chan JCN; Luk A
    PLoS Med; 2020 Sep; 17(9):e1003316. PubMed ID: 32946450
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The impact of phenotype, ethnicity and genotype on progression of type 2 diabetes mellitus.
    Thakarakkattil Narayanan Nair A; Donnelly LA; Dawed AY; Gan S; Anjana RM; Viswanathan M; Palmer CNA; Pearson ER
    Endocrinol Diabetes Metab; 2020 Apr; 3(2):e00108. PubMed ID: 32318630
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pancreatic stellate cells in the islets as a novel target to preserve the pancreatic β-cell mass and function.
    Yang Y; Kim JW; Park HS; Lee EY; Yoon KH
    J Diabetes Investig; 2020 Mar; 11(2):268-280. PubMed ID: 31872946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Different Analysis of
    Duan Y; Sun X; Liu J; Fu J; Wang G
    J Diabetes Res; 2019; 2019():6053604. PubMed ID: 31772943
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Deficiency of Urokinase Plasminogen Activator May Impair β Cells Regeneration and Insulin Secretion in Type 2 Diabetes Mellitus.
    Wu CZ; Ou SH; Chang LC; Lin YF; Pei D; Chen JS
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31756973
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Family history of diabetes in both parents is strongly associated with impaired residual β-cell function in Japanese type 2 diabetes patients.
    Iwata M; Kamura Y; Honoki H; Kobayashi K; Ishiki M; Yagi K; Fukushima Y; Takano A; Kato H; Murakami S; Higuchi K; Kobashi C; Fukuda K; Koshimizu Y; Tobe K
    J Diabetes Investig; 2020 May; 11(3):564-572. PubMed ID: 31705736
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dual GIP-GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential.
    Bastin M; Andreelli F
    Diabetes Metab Syndr Obes; 2019; 12():1973-1985. PubMed ID: 31686879
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacies of Stem Cell Therapies for Functional Improvement of the
    Hwang G; Jeong H; Yang HK; Kim HS; Hong H; Kim NJ; Oh IH; Yim HW
    Int J Stem Cells; 2019 Jul; 12(2):195-205. PubMed ID: 31022997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.